Loading stock data…
BeOne Medicines Ltd. (ONC)
$325.90-0.87 (-0.27%)
Market ClosedLast close Jul 24
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BeOne Medicines AG in the Healthcare sector is trading at $325.90 with a market capitalization of $30.1B. Wall Street consensus targets $415.64 (27 analysts), implying a +27.5% move over the next 12 months. The stock is currently 15% below its 52-week high of $385.22, remaining 3.7% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +27.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.51B↑ | $1.50B↑ | $1.41B↑ | $1.32B↑ | $1.12B |
| Gross Profit | $1.35B↓ | $1.36B↑ | $1.22B↑ | $1.15B↑ | $952.28M |
| Operating Income | $249.90M↑ | $185.03M↑ | $163.11M↑ | $87.89M↑ | $11.10M |
| Net Income | $227.36M↑ | $66.50M↓ | $124.84M↑ | $94.32M↑ | $1.27M |
Peer Comparison
JNJUNHPFE
Fundamentals
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$30.09B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
65.61
Beta
Defensive asset. Lower volatility than the S&P 500.
0.49
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
10.78%
Volume
Today's trading volume
345,707
Recent News
Is BeOne Medicines AG (ONC) Stock Positioned for Growth After Encouraging ASCO Cancer Data?
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. BeOne Medicines AG (NASDAQ:ONC) is one of the most promising stocks on our list. TheFly reported on June 2 that RBC Capital analyst Leonid Timashev increased the firm’s price target on ONC to $436 from $425 while maintaining an Outperform […]
Exchange-Traded Funds Mixed, Equity Futures Lower Pre-Bell Ahead of Key Economic Reports
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up marginally, and the active
Here is Why BeOne (ONC) One of the Most Promising Long-Term Stocks to Buy According to Analysts
BeOne Medicines (NASDAQ:ONC) is one of the most promising long-term stocks to buy according to analysts. On June 1, BeOne presented new clinical data at the 2026 ASCO Annual Meeting, highlighting accelerated progress across three high-priority solid tumor development programs. The data validates the company’s strategy of pairing specific biological targets with advanced modalities, supporting […]
BeOne Medicines (ONC): Citizens Sees an Inflection Point in Its Cancer Pipeline
BeOne Medicines AG (NASDAQ:ONC) is one of the most promising healthcare stocks according to Wall Street analysts. On June 3, Citizens kept its Market Outperform rating and $396 price target on BeOne Medicines AG (NASDAQ:ONC). The firm made the call after BeOne presented robust tumor clinical data at the American Society of Clinical Oncology (ASCO) […]
BeOne Medicines (ONC) Presents Updated BRUKINSA Phase 3 Data at EHA
BeOne Medicines Ltd. (NASDAQ:ONC) is one of the high-growth large-cap stocks to invest in. On June 11, BeOne Medicines Ltd. (NASDAQ:ONC) presented updated Phase 3 clinical data at the European Hematology Association Congress for its approved BTK inhibitor, BRUKINSA. The company markets BRUKINSA as a targeted prescription medication for the treatment of various types of […]